The Cannigma
OCTOBER 11, 2021
The majority of people who use the cannabinoid cannabigerol (CBG) for medical reasons find it to be helpful or very helpful in treating a variety of health conditions, according to the findings of a recent survey. No clinical trial was used in the compilation of the study. who have used it to treat anxiety.
Veriheal
NOVEMBER 17, 2020
Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. Medical cannabis is now available to residents in Ohio who meet one of 22 qualifying conditions laid out by House Bill 523. Strict Guidelines Must be Met Before Conditions Will Be Considered.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Cannabis Law Report
OCTOBER 6, 2021
Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.
NORML
JANUARY 31, 2019
Proposed federal legislation to direct the agency to conduct clinical trials on the use of cannabis for PTSD and for other conditions is currently pending in the US House and Senate. Twenty percent of those surveyed acknowledged having previously used cannabis for medical purposes.
Cannabis Law Report
JUNE 19, 2022
For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. However, that does not mean that the path to patents is closed off.
Cannabis Law Report
NOVEMBER 19, 2021
It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Ensure high quality, timely, and consistent submission of regulatory documents. European Regulatory Lead Executive Summary.
Expert insights. Personalized for you.
132 
Let's personalize your content